Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1990 Aug;74(8):458-61.
doi: 10.1136/bjo.74.8.458.

Oral fluorescein angiography: reassessment of its relative safety and evaluation of optimum conditions with use of capsules

Affiliations
Clinical Trial

Oral fluorescein angiography: reassessment of its relative safety and evaluation of optimum conditions with use of capsules

A P Watson et al. Br J Ophthalmol. 1990 Aug.

Abstract

Injection of fluorescein intravenously for fundal angiography is associated with a high incidence of minor adverse effects (21%) but a very low incidence of serious (life threatening) reactions (0.05%). A serious reaction may occur without warning in a patient with no history of atopy. There are no reports of oral fluorescein causing a serious reaction, and minor adverse effects are uncommon. A study was undertaken to determine optimum conditions for oral fluorescein angiography. Capsules proved more convenient than a solution for ingestion of fluorescein. A dose of 25 mg/kg body weight produced good quality angiograms in 75% of the patients. The best pictures were obtained by photographing the fundus after 40 and 60 minutes.

PubMed Disclaimer

References

    1. Ann Ophthalmol. 1983 Nov;15(11):1084-6 - PubMed
    1. Br J Ophthalmol. 1982 Sep;66(9):567-8 - PubMed
    1. J Pediatr Ophthalmol Strabismus. 1984 Jan-Feb;21(1):33-6 - PubMed
    1. Indian J Ophthalmol. 1984 Sep-Oct;32(5):415-7 - PubMed
    1. Bull Soc Belge Ophtalmol. 1984;211:35-41 - PubMed

Publication types

LinkOut - more resources